No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Express News | JW (Cayman) Therapeutics - Pwc Has Tendered Resignation to Board as Auditor
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Stock Rockets 31% But Many Are Still Ignoring The Company
JW THERAP-B: 2024 INTERIM REPORT
Pharmaron -B (02126) fell 42.80%, now at 1.300 yuan, hitting a 52-week low.
As of 11:34, Wuxi Apptec -B (02126) fell by 42.80% from the previous closing price to 1.300 yuan, hitting a 52-week low; the volume was 0.0227 million shares, with a turnover of 0.0294 million Hong Kong dollars.
